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R ecent years have witnessed a dramatic expansion in our knowledge of the genetic diversity of non–small-cell lung cancer (NSCLC), and in particular 
 adenocarcinoma. This appreciation of the genetic landscape of the disease has resulted 
in the  development of targeted therapies that are directed toward activated oncogenes. 
Several of these drugs have been approved for use in patients and many more are being 
investigated in clinical trials. However, there have been only been limited studies that 
have focused on histologic subtypes within NSCLC and more complete analyses of 
these specific disease entities are needed.
In this issue of the Journal of Thoracic Oncology, Shim et al. explore the genomic 
alterations and clinical characteristics associated with invasive mucinous adenocarcinoma, 
a relatively rare histologic subtype of NSCLC. In confirmation of previous studies that have 
examined the genetic basis of this disease, the authors observed a high rate of KRAS muta-
tion (63%).1 Interestingly, while the G12C variant is the most prevalent KRAS alteration 
in lung adenocarcinoma as a whole, G12D and G12V accounted for the majority (73%) 
of KRAS mutations in this cohort of mucinous adenocarcinomas, with G12C making up 
only 11%. The authors then examined cases lacking KRAS mutation in more detail using 
two targeted deep sequencing approaches. In one, the RNA component of extracted total 
nucleic acid was evaluated for gene rearrangements. They observed that nine of the KRAS 
wild-type cases were positive for rearrangements involving genes that have previously been 
found to be involved in fusions that create oncogenic chimeric proteins. As has been seen 
in other studies examining mucinous adenocarcinoma, rearrangements involving the ERBB 
family ligand NRG1 were particularly prevalent.2–4 By examining genomic DNA by deep 
sequencing using a separate targeted approach, well-characterized activating mutations in 
ERBB2, BRAF, a PIK3CA were detected in four of the KRAS wild-type cases. Notably, 
these oncogenic alterations all occurred independently of each other. However, since the 
deep sequencing approaches were only applied to the initial KRAS wild-type cohort, the 
exclusivity between these activated oncogenes requires further analysis. Nevertheless, 
when taking the initial KRAS mutant cohort into account, the majority (81%) of examined 
cases in the entire cohort were found to be positive for an activated oncogene.
Remarkably, mutations in the tumor suppressor gene TP53, which occur in approxi-
mately 50% of lung adenocarcinomas and commonly overlap with activating oncogenic alter-
ations, were rare in this cohort of mucinous adenocarcinomas, occurring in only two of 50 
evaluated cases. The authors expanded on this finding by querying publicly available TCGA 
lung adenocarcinoma data and found only one TP53 mutated case out of 12 mucinous tumors. 
In the TCGA dataset, the low rate of TP53 mutation correlated with a low mutational burden 
in mucinous versus nonmucinous tumors. While smoking status alone correlated with muta-
tional burden in adenocarcinoma as a whole, multivariate analysis suggested that TP53 status 
likely contributed to low mutational burden in mucinous tumors but that smoking status did 
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not. This has potentially interesting implications for TP53 status 
acting as a surrogate biomarker for mutational burden, which 
itself has been shown to be a potential predictive signature for 
response to immune checkpoint therapy in NSCLC.5
While this study has confirmed the presence and distribu-
tion of previously reported alterations in this disease, several items 
are particularly noteworthy. First, it adds to the body of literature 
which increasingly demonstrates that mucinous adenocarcinoma 
of the lung has distinct molecular features compared with nonmu-
cinous tumors. Second, it underscores the expanding perception 
that gene rearrangements, while existing at relatively low frequen-
cies individually in lung cancer, cumulatively constitute a signifi-
cant fraction of this disease. In mucinous lung adenocarcinoma, 
lung cancer as a whole, and many other solid and hematological 
malignancies, it is becoming increasingly apparent that chimeric 
proteins created by gene rearrangements are the primary onco-
genic driver in a substantial proportion of tumors. Many of these 
fusion proteins can be directly targeted or targeted downstream 
by approved or investigational drugs, making accurate detection 
of rearrangements by diagnostic tests of vital clinical importance. 
Therefore, perhaps the most notable impact of this study lies in the 
methodology used to detect gene fusion events.
Evaluation for rearrangements has traditionally been 
accomplished by cytogenetic techniques, predominantly “break-
apart” fluorescence in-situ hybridization (FISH). However, while 
FISH assays can be multiplexed using multiple fluorophore col-
ors, such assays can be difficult to develop and have limitations to 
the extent to which multiplexing can be accomplished. This can 
make FISH an inefficient approach to examine a large number of 
fusion genes (for example NRG1, BRAF, NTRK1, ALK, ERBB4, 
and RET fusions identified so far by this and other mucinous ade-
nocarcinoma studies).2–4 Reverse transcriptase-polymerase chain 
reaction (RT-PCR) is another traditionally employed rearrange-
ment detection method, but this approach also lacks the ability 
to efficiently multiplex for analysis of many targets. In addition, 
this technique typically relies upon knowing the identity of the 
fusion partner, which is problematic as novel fusion partners 
for the above oncogenes are being continually identified. Next-
generation sequencing (aka deep sequencing) has emerged as a 
strategy to simultaneously assay multiple genetic loci. Indeed, 
two of the previous studies that discovered gene fusions in muci-
nous adenocarcinoma of the lung did so through whole-tran-
scriptome sequencing.2,3 While transcriptome sequencing is ideal 
for discovery efforts, it is not yet an efficient clinical diagnostic 
approach in most laboratories. This is due to a need for high depth 
of coverage and a need for high throughput (to accommodate 
many patient samples at once) in the clinical realm. Therefore, 
most next-generation sequencing assays used for clinical diag-
nostic purposes rely on target enrichment approaches and focus 
on subsets of genes that are potentially clinically relevant. While 
this approach is relatively straight-forward for identifying single 
nucleotide variants and small insertions and deletions, the detec-
tion of larger structural rearrangements (including gene fusions) 
is more challenging. For example, if using an amplicon-based 
target enrichment technique to detect a fusion event, primer sets 
are needed that span the breakpoint, meaning that a priori knowl-
edge of the fusion partner is required (similar to RT-PCR). The 
study by Shim et al. circumvents this problem by employing a 
recently reported variation of amplicon-based target enrichment: 
anchored multiplex PCR (AMP).6
In AMP, cDNA made from extracted RNA or total nucleic 
acid is processed and ligated to a “half-functional adapter” (sim-
ilar to an adapter used for standard next- generation sequencing 
although incomplete). Then, a PCR technique using one primer 
specific to the oncogene component of the fusion and another 
primer specific to the half-functional adapter is performed. If 
a particular sequence contains a fusion break point, then the 
sequence surrounding the breakpoint is amplified by virtue of 
being between the gene-specific and adapter-specific primers. 
This step is followed by an additional nested PCR round that 
completes the creation of functional adapters on both ends of 
the sequence, making clonal amplification for next-generation 
sequencing possible. Importantly, by employing a universal 
primer to the half-functional adapter, the need for a primer 
complimentary to the fusion partner is bypassed. Thus, most 
fusions, including fusions to previously unknown partners, 
are detected for each fusion oncogene that is examined. One 
caveat of this assay is that some foreknowledge of breakpoints 
is still needed, because some rearrangements may occur within 
unexpected introns or fuse the partner gene at the opposite end 
(i.e., 3′ instead of 5′); although this can easily be overcome by 
broader and bi-directional design. Importantly, this assay can 
be performed in multiplex fashion (using primers to multiple 
oncogenes involved in fusions), and, due to the amplification 
steps, can be performed on low nucleic acid inputs, making it 
highly adaptable for the clinical setting.
As the list of known activated oncogenes increases and 
the arsenal of targeted therapies for cancer grows, there will 
be an ever-increasing need to simultaneously detect multi-
ple types of oncogenic alterations. The study by Shim et al. 
exemplifies how multiple next-generation sequencing library 
preparation techniques can be combined to obtain a more 
complete assessment of the activated oncogenes in a tumor 
sample. Using this approach, they reveal a distinct portrait 
of the genetic landscape of mucinous adenocarcinoma of the 
lung and highlight differences between this histologic subtype 
and NSCLC as a whole. Ultimately, approaches such as these 
will serve a critical role in the identification of patients for 
oncogene-targeted therapies.
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